Dr. Jason Porter details groundbreaking research for KRAS-mutant NSCLC during a Targeted Oncology Community Case Forum. 🎉 Explore the CodeBreaK 100 and CodeBreaK 200 studies, showing promising results and insights into new treatment strategies. Read more about the accelerated approval of new treatment options, and their impact on patients’ lives. Let’s revolutionize #LungCancer care together!… Read more »